Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07798505
PHASE1
A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers
Sponsor: Hemab ApS
View on ClinicalTrials.gov
Summary
The purposes of this clinical study are 1. To see how the new drug (HMB-003) under study is tolerated in healthy volunteers, and if there are any important side effects. 2. To measure the amount of HMB-003 in the body after injection.
Key Details
Gender
All
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-08-17
Completion Date
2027-04-30
Last Updated
2026-09-01
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
HMB-003
HMB-003 will be administered subcutaneously as a single dose
DRUG
Placebo
Placebo will be administered subcutaneously as a single dose of placebo.
Locations (1)
Worldwide Clinical Trials
San Antonio, Texas, United States